Manuela Schmidinger

Summary

Affiliation: Medical University of Vienna
Country: Austria

Publications

  1. ncbi request reprint Major response and clinical benefit following third-line treatment for Bellini duct carcinoma
    Negar Fakhrai
    Division of Clinical Oncology, Department of Medicine I, Medical University of Vienna, Austria
    Wien Klin Wochenschr 117:63-5. 2005
  2. doi request reprint Novel agents for renal cell carcinoma require novel selection paradigms to optimise first-line therapy
    Manuela Schmidinger
    Department of Medicine I and Cancer Center, Clinical Division of Oncology, Medical University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Cancer Treat Rev 35:289-96. 2009
  3. doi request reprint Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma
    Manuela Schmidinger
    Department of Medicine I, Clinical Division of Oncology and Cancer Center, Medical University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Cancer Treat Rev 36:416-24. 2010
  4. doi request reprint Optimizing the use of sunitinib in metastatic renal cell carcinoma: an update from clinical practice
    Manuela Schmidinger
    University of Vienna, Vienna, Austria
    Cancer Invest 28:856-64. 2010
  5. ncbi request reprint Dose escalation and pharmacokinetics study of enzastaurin and sunitinib versus placebo and sunitinib in patients with metastatic renal cell carcinoma
    Manuela Schmidinger
    Department of Medicine I and Cancer Center, Clinical Division of Oncology, Medical University of Vienna, Vienna, Austria
    Am J Clin Oncol 35:493-7. 2012
  6. doi request reprint Therapy management of cardiovascular adverse events in the context of targeted therapy for metastatic renal cell carcinoma
    Manuela Schmidinger
    Department of Oncology, Medical University of Vienna, Vienna, Austria
    Int J Urol 19:796-804; author reply 805. 2012
  7. doi request reprint Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma
    Manuela Schmidinger
    Clinical Division of Oncology, Department of Medicine I and Cancer Center, Medical University of Vienna, Vienna, Austria
    J Clin Oncol 26:5204-12. 2008
  8. ncbi request reprint Management of cardiac adverse events occurring with sunitinib treatment
    Manuela Schmidinger
    Medical University of Vienna, Department of Medicine I and Cancer Center, Clinical Division of Oncology, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Anticancer Res 29:1627-9. 2009
  9. doi request reprint Hypothyroidism in patients with renal cell carcinoma: blessing or curse?
    Manuela Schmidinger
    Clinical Division of Oncology, Department of Medicine I and Cancer Center, Medical University of Vienna, Vienna, Austria
    Cancer 117:534-44. 2011
  10. ncbi request reprint Aldesleukin in advanced renal cell carcinoma
    Manuela Schmidinger
    Department of Medicine I, Clinical Division of Oncology, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Expert Rev Anticancer Ther 4:957-80. 2004

Detail Information

Publications29

  1. ncbi request reprint Major response and clinical benefit following third-line treatment for Bellini duct carcinoma
    Negar Fakhrai
    Division of Clinical Oncology, Department of Medicine I, Medical University of Vienna, Austria
    Wien Klin Wochenschr 117:63-5. 2005
    ..Histopathologic characteristics should be a major criterion for treatment strategy in renal carcinoma, particularly in Bellini duct carcinoma...
  2. doi request reprint Novel agents for renal cell carcinoma require novel selection paradigms to optimise first-line therapy
    Manuela Schmidinger
    Department of Medicine I and Cancer Center, Clinical Division of Oncology, Medical University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Cancer Treat Rev 35:289-96. 2009
    ....
  3. doi request reprint Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma
    Manuela Schmidinger
    Department of Medicine I, Clinical Division of Oncology and Cancer Center, Medical University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Cancer Treat Rev 36:416-24. 2010
    ....
  4. doi request reprint Optimizing the use of sunitinib in metastatic renal cell carcinoma: an update from clinical practice
    Manuela Schmidinger
    University of Vienna, Vienna, Austria
    Cancer Invest 28:856-64. 2010
    ..These strategies may allow long-term sunitinib treatment, thereby optimizing the available clinical efficacy...
  5. ncbi request reprint Dose escalation and pharmacokinetics study of enzastaurin and sunitinib versus placebo and sunitinib in patients with metastatic renal cell carcinoma
    Manuela Schmidinger
    Department of Medicine I and Cancer Center, Clinical Division of Oncology, Medical University of Vienna, Vienna, Austria
    Am J Clin Oncol 35:493-7. 2012
    ..To assess antiangiogenic effects of enzastaurin in combination with sunitinib in patients with renal cell carcinoma (RCC)...
  6. doi request reprint Therapy management of cardiovascular adverse events in the context of targeted therapy for metastatic renal cell carcinoma
    Manuela Schmidinger
    Department of Oncology, Medical University of Vienna, Vienna, Austria
    Int J Urol 19:796-804; author reply 805. 2012
    ..Implementation of therapy management measures contributes towards maximizing treatment outcomes with targeted agents in patients with metastatic renal cell carcinoma...
  7. doi request reprint Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma
    Manuela Schmidinger
    Clinical Division of Oncology, Department of Medicine I and Cancer Center, Medical University of Vienna, Vienna, Austria
    J Clin Oncol 26:5204-12. 2008
    ..TKI-associated cardiotoxicity was reported in approximately 10% of the patients. Detailed cardiovascular monitoring during TKI treatment may reveal early signs of myocardial damage...
  8. ncbi request reprint Management of cardiac adverse events occurring with sunitinib treatment
    Manuela Schmidinger
    Medical University of Vienna, Department of Medicine I and Cancer Center, Clinical Division of Oncology, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Anticancer Res 29:1627-9. 2009
    ..The patient was at poor prognostic risk, with an Eastern Cooperative Oncology Group performance status of 3...
  9. doi request reprint Hypothyroidism in patients with renal cell carcinoma: blessing or curse?
    Manuela Schmidinger
    Clinical Division of Oncology, Department of Medicine I and Cancer Center, Medical University of Vienna, Vienna, Austria
    Cancer 117:534-44. 2011
    ..The objective of this analysis was to investigate whether the occurrence of hypothyroidism during treatment with sunitinib and sorafenib affects the outcome of patients with mRCC...
  10. ncbi request reprint Aldesleukin in advanced renal cell carcinoma
    Manuela Schmidinger
    Department of Medicine I, Clinical Division of Oncology, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Expert Rev Anticancer Ther 4:957-80. 2004
    ..It appears that factors other than those that are treatment related are responsible for the course of the disease...
  11. doi request reprint Defining risk status in the first-line treatment of metastatic renal cell carcinoma
    Manuela Schmidinger
    Department of Medicine I, Clinical Division of Oncology, Medical University of Vienna, Waehringer Guertel 18 20, 1090 Vienna, Austria
    J Cancer Res Clin Oncol 136:961-8. 2010
    ..Additionally, the evidence supporting the use of targeted agents in patients with mRCC according to their risk status is reviewed...
  12. pmc Extracerebral metastases determine the outcome of patients with brain metastases from renal cell carcinoma
    Ursula M Vogl
    Department of Medicine I, Clinical Division of Oncology and Cancer Center, Medical University Vienna, Vienna, Austria
    BMC Cancer 10:480. 2010
    ..The aim of this analysis was to compare the outcome of patients with and without BM in the era of targeted agents...
  13. doi request reprint Synergistic effect of Sorafenib and Sunitinib with Enzastaurin, a selective protein kinase C inhibitor in renal cell carcinoma cell lines
    Ursula Maria Vogl
    Clinical Division of Oncology, Department of Medicine I, Medical University Vienna, Waehringer Guertel 18 20, Vienna, Austria
    Cancer Lett 277:218-26. 2009
    ..The combination of Enzastaurin with Sorafenib and Sunitinib seems highly encouraging and warrants further investigation in vivo...
  14. doi request reprint Safety and efficacy of temsirolimus in heavily pretreated patients with metastatic renal cell carcinoma
    Wolfgang Lamm
    Clinical Division of Oncology and Cancer Centre, Department of Medicine I, Medical University of Vienna, Austria
    Acta Oncol 51:101-6. 2012
    ..The role of temsirolimus in pretreated patients with any risk profile is unclear. The aim of this retrospective analysis was to investigate the impact of temsirolimus in patients who had progressed on various treatment lines...
  15. doi request reprint Phase II study of docetaxel in combination with oxaliplatin in patients with metastatic or locally advanced esophagogastric cancer previously untreated with chemotherapy for advanced disease: results of the Central European Cooperative Oncology Group Stud
    Michael Hejna
    Department of Internal Medicine I, Division of Oncology, Medical University of Vienna, Vienna, Austria
    Anticancer Drugs 19:535-9. 2008
    ..Our data suggest that the combination of docetaxel and oxaliplatin with granulocyte colony-stimulating factor and erythropoietin has a promising therapeutic index in patients with advanced gastroesophageal adenocarcinoma...
  16. ncbi request reprint Palliative chemotherapy for recurrent and metastatic esophageal cancer
    Birgit Grünberger
    Department of Internal Medicine I, Division of Oncology, University of Vienna, Austria
    Anticancer Res 27:2705-14. 2007
    ..Prognosis for the majority of patients, however, remains poor as increases in survival were moderate at best...
  17. ncbi request reprint Combined analysis of two phase II trials in patients with primary and advanced breast cancer with epidoxorubicin and docetaxel+granulocyte colony stimulating factor
    Catharina Wenzel
    Department of Internal Medicine I, Division of Oncology, University Hospital of Vienna, 1090 Vienna, Austria
    Anticancer Drugs 13:67-74. 2002
    ..Thus, this regimen can be considered for further clinical trials...
  18. doi request reprint Tumor grade is associated with venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study
    Jonas Ahlbrecht
    The Medical University of Vienna, Vienna, Austria
    J Clin Oncol 30:3870-5. 2012
    ..Currently, only scarce information on the association between tumor grade and VTE is available. We thus evaluated the role of tumor grade and its association with VTE...
  19. ncbi request reprint Postoperative chemotherapy for gastric cancer
    Michael Hejna
    Department of Internal Medicine I, Division of Oncology, University of Vienna, Austria
    Oncologist 11:136-45. 2006
    ..The objective of this article is to review briefly the clinical trials available in the current literature using adjuvant cytotoxic chemotherapy in patients with gastric cancer after potentially curative surgical resection...
  20. ncbi request reprint Aerobic exercise as additive palliative treatment for a patient with advanced hepatocellular cancer
    Richard Crevenna
    Department of Physical Medicine and Rehabilitation, University of Vienna, Wahringer Gurtel 18 20, A 1090 Vienna, Austria
    Wien Med Wochenschr 153:237-40. 2003
    ..Nevertheless, aerobic exercise initiated and executed with appropriate care may serve as a useful additional means of palliative treatment in some patients with advanced cancer...
  21. doi request reprint Rechallenge with mTOR Inhibitors in Metastatic Renal Cell Carcinoma Patients Who Progressed on Previous mTOR Inhibitor Therapy
    Agnes Maj-Hes
    Department of Urology, Kaiser Franz Josef Spital, Vienna, Austria
    Oncology 85:8-13. 2013
    ..2 months) and 5.8 months (2.9-19.3 months), respectively. Conclusions: Despite the limited number of patients, this highlights the feasibility of utilizing mTOR rechallenge as an integral part of sequential treatment strategies in mRCC. ..
  22. pmc Experience with sunitinib in the treatment of metastatic renal cell carcinoma
    Manuela Schmidinger
    Clinical Division of Oncology, Department of Medicine I, Medical University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Ther Adv Urol 4:253-65. 2012
    ....
  23. ncbi request reprint Neuromuscular electrical stimulation for a patient with metastatic lung cancer--a case report
    Richard Crevenna
    Department of Physical Medicine and Rehabilitation, Vienna Medical University, Waehringer Guertel 18 20, A 1090, Vienna, Austria
    Support Care Cancer 14:970-3. 2006
    ....
  24. ncbi request reprint Psychometric- and quality-of-life assessment in long-term glioblastoma survivors
    Manuela Schmidinger
    First Medical Department, Division of Clinical Oncology, University of Vienna, Vienna, Austria
    J Neurooncol 63:55-61. 2003
    ..We evaluated the subjective QOL, clinical psychophysiological and cognitive functions in patients with GBM surviving 18 months after diagnosis...
  25. ncbi request reprint Quality of life in patients with non-metastatic differentiated thyroid cancer under thyroxine supplementation therapy
    Richard Crevenna
    Department of Physical Medicine and Rehabilitation, University of Vienna, Austria
    Support Care Cancer 11:597-603. 2003
    ..This was a cross-sectional study to evaluate health-related quality of life (HRQOL) and to identify rehabilitation needs of patients with non-metastatic thyroid cancer under thyroxine supplementation therapy...
  26. ncbi request reprint [Aerobic endurance training for cancer patients]
    Richard Crevenna
    Universitätsklinik für Physikalische Medizin und Rehabilitation, Universitätsklinik für Innere Medizin I, Wien
    Wien Med Wochenschr 153:212-6. 2003
    ..It enables these patients to recover their physical function and to return to an active lifestyle. Aerobic exercise seems to be an effective possibility to reduce sequelae of cancer and to increase quality of life...
  27. ncbi request reprint [Aerobic physical training in a breast cancer patient with inflammatory recurrence]
    R Crevenna
    Universitätsklinik für Physikalische Medizin und Rehabilitation, Wahringer Gurtel 18 20, A 1090 Wien
    Wien Med Wochenschr 152:581-4. 2002
    ..This case report demonstrates feasibility and benefits of aerobic exercise for a patient with advanced breast cancer undergoing palliative treatment...
  28. ncbi request reprint Capecitabine in the treatment of metastatic renal cell carcinoma failing immunotherapy
    Catharina Wenzel
    Department of Internal Medicine I, Division of Oncology, the Ludwig Boltzmann Institute for Clinical Oncology, University Hospital of Vienna, Austria
    Am J Kidney Dis 39:48-54. 2002
    ....
  29. ncbi request reprint [Management of capecitabine-induced hand-foot syndrome by local phytotherapy]
    Elisabeth Kern
    Anstaltsapotheke des Krankenhauses der Barmherzigen Schwestern, Linz, Austria
    Wien Med Wochenschr 157:337-42. 2007
    ....